BioSpectrum (Asia) - - ANALYSIS -

● July 5 - CFDA and the Jilin Provin­cial Bu­reau con­ducted a flight in­spec­tion of Changchun Chang­sheng Biotech­nol­ogy Co., Ltd

● July 15 - CFDA and the Jilin Provin­cial Bu­reau con­ducted com­pre­hen­sive in­ves­ti­ga­tions

● July 22 – is­sued no­tice on Changchun Chang­sheng Biotech­nol­ogy Co., Ltd. for its il­le­gal pro­duc­tion of freeze-dried hu­man ra­bies vac­cine

● July 23 - na­tion’s drug reg­u­la­tor held an en­larged meet­ing to study and im­ple­ment the mea­sures

● Au­gust 7 - CFDA is­sued a cir­cu­lar re­lated to re ad­min­is­tra­tion of for­mu­lated Vac­ci­na­tion pro­gramme in the af­fected lo­ca­tions

● Au­gust 17 - State Ad­min­is­tra­tion of Mar­ket Su­per­vi­sion dis­missed 6 se­nior SFDA of­fi­cials

● Septem­ber 7 – SFDA said af­ter thor­ough in­ves­ti­ga­tion of the vac­cine pro­duc­tion en­ter­prises and found no im­pact on the qual­ity and safety of vac­cines.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.